|
|
|
|
||
Re: CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA "Clawback" in this case would be the return of any shares execs received as a result of the submission of the "supposed completed" BLA submission.. (plus any penalties).. [I believe Team was awarded significant amount of shares for the "submission" which they may have subsequently sold..] |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
12520 | Re: CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA | DonPA | 0 | 10/28/2021 1:14:57 PM |